Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Hadassah Hosts Israel Heart Society Conference Highlighting Israel’s Cardiac Innovations

With Prof. Chaim Lotan, head of Hadassah's Heart Institute and Outgoing President of the Israel Heart Society (IHS) as host along with IHS Secretary-General Dr. Amit Segev, over 1,000 cardiologists from around the world participated in the IHS's international conference in Jerusalem, celebrating its 60th anniversary and spotlighting Israel's major contributions to the treatment of cardiovascular disease.

Commemorating three of these cardiac contributions, Israel's Philatelic Service recently issued three new postage stamps. One features a percutaneous (inserted through the skin) artificial heart valve; another highlights stents (metal mesh cylinders that release medication and hold open damaged or collapsed coronary arteries); and a third contains an illustration of an implanted defibrillator that electrically regulates a heartbeat. The stamps were unveiled at the IHS conference by Philatelic Service Director Yaron Razon.

Among the leading foreign guests at the conference were American College of Cardiology President Prof. John Harold and European Society of Cardiology President Prof. Panos Vardas. In an interview with The Jerusalem Post, Prof. Harold, a cardiologist at Cedar-Sinai Medical Center in California, related that he has trained many Israeli cardiologists and described the growth of cardiac services in Israel as "nothing short of extraordinary." He also commented: "Israeli cardiologists have great bench-to-bedside developments. Israel is one of the safest parts of the world to have a heart attack."

Prof. Lotan told the audience that the mortality rate from cardiovascular disease has dropped in recent decades by half, and that 90 percent of acute cardiovascular events are treated immediately with catheterization. In addition, he noted that in the last four years, about 1,500 artificial heart valves have been implanted via catheter to replace faulty ones in patients for whom open-heart surgery is counterindicated.

Read more in The Jerusalem Post>>
Date: 4/30/2013


More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America